IANS

Ionis Pharmaceuticals is a leading biotechnology company specializing in RNA-targeted therapeutics, particularly antisense technology. Founded in 1989, the company has pioneered the development of antisense oligonucleotides (ASOs) to treat a wide range of diseases, including rare genetic disorders, cardiovascular conditions, and neurological diseases. Ionis has successfully brought several medicines to market, most notably Spinraza for spinal muscular atrophy and Wainua for ATTR polyneuropathy. The company maintains a robust pipeline and extensive partnerships with major pharmaceutical firms like Biogen and AstraZeneca to commercialize its innovative RNA-based therapies. Their proprietary platform allows for the precise targeting of disease-causing RNAs, offering potential treatments for previously undruggable targets.